New medicaments for the treatment of psoriasis vulgaris are based on fumaric acid monoethyl ester (I) and its mineral salts, and contain (a) polyethylene glycols which are water-soluble and which are liquid, melt at body temp. or are solid, (b) isopropyl myristate, which is fat-soluble and liquid, and/or (c) isopropyl palmitate, which is fat-soluble and melts at body temp. The use of (a), and (b) and/or (c) adjuvants gives preparations in which (I) and its mineral salts are stable and in which the adjuvants are not adversely affected by the active components. The active components may be present in the medicaments in dissolved form, and their release can be controlled. The preparations may be fat- or water-soluble.
展开▼
